XT
NBIX icon

XTX Topco’s Neurocrine Biosciences NBIX Stock Holding History

XTX Topco’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.57M Buy
+27,124
New +$4.02M 0.06% 430
2026
Q1 		– Sell
-11,775
Closed -$1.67M – 4178
2025
Q4 		$1.67M Buy
11,775
+9,013
+326% +$1.31M 0.04% 683
2025
Q3 		$388K Sell
2,762
-22,255
-89% -$3.02M 0.02% 1290
2025
Q2 		$3.14M Buy
25,017
+5,463
+28% +$626K 0.13% 177
2025
Q1 		$2.16M Buy
19,554
+12,688
+185% +$1.61M 0.11% 233
2024
Q4 		$937K Sell
6,866
-1,799
-21% -$223K 0.08% 339
2024
Q3 		$998K Buy
8,665
+5,322
+159% +$730K 0.07% 429
2024
Q2 		$460K Sell
3,343
-4,464
-57% -$612K 0.04% 698
2024
Q1 		$1.08M Buy
7,807
+3,342
+75% +$456K 0.15% 139
2023
Q4 		$588K Buy
4,465
+1,200
+37% +$138K 0.13% 179
2023
Q3 		$367K Sell
3,265
-5,243
-62% -$552K 0.06% 593
2023
Q2 		$802K Buy
8,508
+4,080
+92% +$399K 0.14% 153
2023
Q1 		$448K Buy
4,428
+19
+0.4% +$1.98K 0.09% 363
2022
Q4 		$527K Buy
4,409
+1,402
+47% +$164K 0.11% 276
2022
Q3 		$319K Sell
3,007
-507
-14% -$51.4K 0.08% 464
2022
Q2 		$343K Buy
+3,514
New +$324K 0.14% 228

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's NBIX Position: Q2 2026 in Review

XTX Topco opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 27,124 shares worth $4.57M. The stake represents 0.06% of the portfolio and ranks #430 among its holdings. This is a return to the name: XTX Topco previously reported a position in NBIX as recently as Q4 2025.

XTX Topco first reported a position in NBIX in Q2 2022 and has held it in 16 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • XTX Topco held 27,124 shares of Neurocrine Biosciences worth $4.57M as of Q2 2026.
  • Neurocrine Biosciences was a new XTX Topco position in Q2 2026.
  • Neurocrine Biosciences made up 0.06% of XTX Topco's portfolio in Q2 2026, its #430 holding.
  • XTX Topco first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 16 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.